A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Alpelisib (Primary) ; Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- Sponsors Novartis
- 12 Sep 2017 Planned End Date changed from 1 Jul 2017 to 28 Dec 2018.
- 12 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 28 Dec 2018.
- 13 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.